Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center

Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Zachert C, Kaemmerer D, Petrovitch A,

Keywords: PRRT,

#238 Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?

Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hoersch D, Zachert C, Baum R,

Keywords: single kidney, non-functional kidney, peptide receptor radionuclide therapy, NET,

#236 Very Long-term Follow-up (> 5 years) of Renal Function of Neuroendocrine Tumor Patients Treated with Five or More Cycles of Peptide Receptor Radionuclide Therapy (PRRNT)

Introduction: Nephrotoxicity is one of the primary concerns in neuroendocrine tumor (NET) patients (pts.) treated with peptide receptor radionuclide therapy (PRRNT).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hoersch D, Zachert C, Hommann M, Baum R,

Keywords: Peptide Receptor Radionuclide Therapy, NET, nephrotoxicity, long-term follow-up,

#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors

Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Prasad V, Roether M, Zachert C, Baum R,

Keywords: Peptide Receptor Radionuclide Therapy (PRRT), low dose multiple cycle, well-differentiated neuroendocrine tumors,

#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs

Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Prasad V, Budiawan H, Ali S, Hoersch D, Zachert C,

Keywords: Peptide Receptor Radionuclide Therapy (PRRT), thyroid cancer, survival, toxicity, response,